NCT06048250
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
At risk: Primary completion moved at least 4 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 7 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria revised
- Enrollment closed, study ongoing
- Primary and study completion pushed from Sep 21, 2026 to Feb 9, 2027
- Site details revised
- Notable Primary and study completion dates: Mar 21, 2026 to Sep 21, 2026v7
- Minor Start date changed from estimate of Mar 28, 2024 to Apr 9, 2024v5
- Notable Start date: Dec 28, 2023 to Mar 28, 2024v4
- Notable Primary and study completion dates: Jul 12, 2025 to Mar 21, 2026
- Start date: Oct 11, 2023 to Dec 28, 2023
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
Starting between 30 and 90 days after infusion of idecabtagene vicleucel, patients receive mezigdomide PO on days 1-21 or days 1-14 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT during screening. Patients also undergo bone marrow aspiration and blood sample collection throughout the study.
Procedures: Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography, Positron Emission Tomography
Biologicals: Mezigdomide
Sites
1 site in 1 country
- City of Hope Medical CenterDuarte, California, United States